Neotigason Use In Pregnancy & Lactation

Women of childbearing potential / Contraception in males and females: See Warnings.
Neotigason is highly teratogenic. Its use is contraindicated not only in pregnant women and women who might become pregnant during or within 3 years of the cessation of treatment, but in all women of childbearing potential. The risk of giving birth to a deformed child is exceptionally high if Neotigason is taken before or during pregnancy, no matter for how long or at what dosage.
Primary contraceptive method can be a combination hormonal contraceptive product or an intrauterine device and it is recommended that a condom or diaphragm (cap) is also used. Low dose progesterone-only products (minipills) are not recommended due to indications of possible interference with their contraceptive effect.
For male patients treated with Neotigason, available data, based on the level of maternal exposure from the semen and seminal fluid indicate a minimal, if any, risk of teratogenic effects.
Pregnancy: Neotigason is contraindicated in pregnant women (see Contraindications).
Breastfeeding: Neotigason must not be given to nursing mothers (see Contraindications).